“DelveInsight’s Coronary Artery Disease Pipeline Insight 2022 report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Coronary Artery Disease pipeline landscape”
Coronary Artery Disease pipeline report covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
For Coronary Artery Disease emerging drugs, the Coronary Artery Disease pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Coronary Artery Disease pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key takeaways from the Coronary Artery Disease Pipeline Report
Get to know more in-depth information about the Coronary Artery Disease Pipeline Report, click here: Coronary Artery Disease Pipeline Insight
Coronary Artery Disease Overview
Coronary artery disease is the most common type of heart disease in the United States. It is sometimes called coronary heart disease or ischemic heart disease. CAD is caused by plaque buildup in the walls of the arteries that supply blood to the heart (called coronary arteries) and other parts of the body.Plaque is made up of deposits of cholesterol and other substances in the artery. Plaque buildup causes the inside of the arteries to narrow over time, which can partially or totally block the blood flow. This process is called atherosclerosis. Angina, or chest pain and discomfort, is the most common symptom of Coronary Artery Disease.
Coronary Artery Disease Pipeline Insight Report
Coronary Artery Disease Pipeline Insight 2022 report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Coronary Artery Disease pipeline landscape is provided which includes the disease overview and Coronary Artery Disease treatment guidelines. The assessment part of the report embraces, in depth Coronary Artery Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Coronary Artery Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Coronary Artery Disease Emerging Drugs
Selatogrel: Idorsia Pharmaceuticals
Selatogrel, is a small molecule being developed by Idorsia Pharmaceuticals. It acts as a P2Y12 receptor antagonist. Currently, the drug is being studied in Phase II stage of Clinical trial evaluation for the treatment of Coronary artery disease.
Atuliflapon: AstraZeneca
Atuliflapon (formerly AZD 5718) is an orally available, small molecule, 5-lipoxygenase activating protein inhibitor, being developed by AstraZeneca. Currently, the drug is being studied in Phase II stage of clinical trial evaluation for the treatment of Coronary artery disease.
XTR 003: Sinotau Pharmaceuticals
XTR003 is a PET imaging radiopharmaceutical agent used to trace myocardial fatty acid metabolism. XTR003 is a modified fatty acid that enters the myocytes and passes through mitochondrial membrane by the same process as the natural existing fatty acids and then undergoes partial β-oxidation before being trapped in the mitochondria. In preclinical study XTR003 showed high myocardial uptake and retention. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Coronary Artery Disease.
Coronary Artery Disease Pipeline Therapeutics Analysis
There are approx. 30+ key companies which are developing the therapies for Coronary Artery Disease. The companies which have their Coronary Artery Disease drug candidates in the most advanced stage, i.e. Phase II include, Idorsia Pharmaceuticals.
Coronary Artery Disease Pipeline Phases
DelveInsight’s report covers around 30+ products under different phases of clinical development like
For further information about Coronary Artery Disease treatment and pipeline therapies, visit @ Coronary Artery Disease Pipeline Assessment
Coronary Artery Disease Pipeline Analysis
The report provides insights into:
The Coronary Artery Disease report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Scope of the Coronary Artery Disease Pipeline Report
Table of content
Got Queries? Reach out for more information @ Coronary Artery Disease Clinical Trials
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/